Brookline Capital Management Estimates Palisade Bio FY2024 Earnings

Palisade Bio, Inc. (NASDAQ:PALI) – Analysts at Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Palisade Bio in a research note issued to investors on Wednesday, November 20th. Brookline Capital Management analyst K. Raja expects that the company will earn ($11.74) per share for the year. Brookline Capital Management has a “Buy” rating and a $38.00 price objective on the stock. The consensus estimate for Palisade Bio’s current full-year earnings is ($13.11) per share. Brookline Capital Management also issued estimates for Palisade Bio’s Q4 2024 earnings at ($2.39) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.23) EPS, FY2027 earnings at ($2.04) EPS and FY2028 earnings at ($2.42) EPS.

Separately, Maxim Group lowered their price target on Palisade Bio from $22.50 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Palisade Bio Stock Performance

Shares of NASDAQ:PALI opened at $2.44 on Monday. The company has a market cap of $3.24 million, a price-to-earnings ratio of -0.17 and a beta of 1.36. Palisade Bio has a 12 month low of $2.18 and a 12 month high of $22.35. The company has a 50-day moving average price of $3.21 and a 200 day moving average price of $3.96.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($2.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.35) by $1.03.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.